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Abstract
Background Orally available ticagrelor in combination
with low-dose aspirin (75–100 mg/day) is indicated for
adult patients with acute coronary syndromes. However,
patients with swallowing difficulties may be unable to
consume the currently available 90-mg tablet. It is
hypothesized that ticagrelor could be given to this patient
cohort as a crushed dose administered either orally or via a
naso-gastric (NG) tube.
Objectives To investigate the potential use of crushed
ticagrelor tablets (90- and 180-mg doses) for oral dose or
NG tube administration.
Methods Ticagrelor tablets (90 or 180 mg [two 90-mg
tablets]) were prepared to emulate oral and NG tube
administration by similar methods. For the oral dose,
ticagrelor tablets were crushed using a mortar and pestle and
transferred to a dosing cup. 100 mL of water was added to
the mortar, stirred, and the contents were transferred to the
dosing cup and stirred to form a suspension. At this stage,
where the suspension would normally be administered to a
patient, it was collected for high performance liquid
chromatography (HPLC) analysis. The mortar was then
flushed with 100 mL of water, and the contents were again
transferred to the dosing cup, stirred, and collected for
HPLC analysis. For the NG dose, polyvinylchloride,
polyurethane, and silicone size CH10 NG tubes were used.
The tablets were crushed using a mortar and pestle, diluted
with 50 mL of water, and stirred. At this stage, where the
suspension would normally be administered to a patient
through an NG tube using a syringe, it was collected for
HPLC analysis. The mortar was then flushed with two
additional 50 mL aliquots of water and the contents were
passed through the NG tube. HPLC analysis examined the
recoverability of ticagrelor in each of the dose suspensions
and flushes and the stability of the suspension when held in
a syringe for up to 2 h.
Results One or two crushed 90-mg ticagrelor tablets,
prepared for either oral or NG tube administration, delivers
a mean dose of C97 % of the original tablet. No degra-
dation of the suspensions was detected after ticagrelor had
been held in the syringe for up to 2 h.
Conclusion Although not an approved method of
administration, these results suggest that ticagrelor tablets
can be crushed and prepared for oral administration or for
administration via an NG tube. From a clinical perspective,
a syringe hold-time of up to 2 h should allow for enough
time between preparation and administration (orally or via
an NG tube) of the dispersed tablets to the patient. Future
studies are required to test the effect of crushed dosing on
pharmacokinetic and pharmacodynamic parameters.
1 Introduction
Acute coronary syndromes (ACS) encompass a range of
myocardial ischemic events that represent a significant
clinical concern worldwide [1, 2]. ACS is typically
categorized as either ST segment elevation (STE-) ACS or
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non-STE ACS (NSTE-ACS), and NSTE-ACS can be fur-
ther categorized into non-STE myocardial infarction and
unstable angina [1]. The current recommended treatment
for patients with ACS is dual antiplatelet therapy; aspirin is
taken in combination with another agent to inhibit platelet
activity, preventing the development of this condition [3].
The thienopyridines, clopidogrel and prasugrel, are oral
antiplatelet drugs that irreversibly inhibit the P2Y12 puri-
noreceptor [4], whereas ticagrelor, a first-in-class cyclo-
pentyltriazolopyrimidine, is a reversibly binding, oral
P2Y12 receptor antagonist [5]. Pharmacologic studies have
shown that ticagrelor has a rapid onset of activity and
enhanced inhibition of platelet aggregation compared with
clopidogrel [6–8]. In addition, the large phase III PLATelet
inhibition and patient Outcomes (PLATO) clinical trial has
also reported that ticagrelor compared with clopidogrel
significantly reduces the incidence of myocardial infarc-
tion, stroke, or death from vascular causes without an
increase in the rates of major bleeding in patients with ACS
[9].
Ticagrelor (180-mg loading dose, 90 mg twice daily) is
currently recommended for combination antiplatelet treat-
ment with low-dose aspirin (150–300-mg loading dose,
75–100 mg a day) for patients with ACS [1, 3, 10]. Most
P2Y12 inhibitors used in ACS treatment, including ticagr-
elor, are only available in an oral form. This limitation
represents a potential concern for patients with difficulty
swallowing tablets, which in the general population may be
as high as 40 % of all adults [11, 12]. In the elderly,
swallowing difficulties are even more prevalent; nearly
60 % of individuals (ages 60–89 years) indicate they have
difficulties in swallowing tablets/capsules [13]. Difficulties
with swallowing can also lead to noncompliance with
treatment medication. Of those adults in the general pop-
ulation with swallowing difficulties, 14 % reported that
they have delayed taking their prescribed medication and
8 % reported that they have skipped their medication
entirely [11, 12]. In the elderly population, 68 % of indi-
viduals with swallowing difficulties reported they had to
crush or open a tablet in order to swallow the medication
and 69 % reported they have missed dose(s) because the
tablet/capsule was too difficult to swallow [13]. In addition
to patients with swallowing difficulties, patients who are
unconscious when they arrive in the emergency room or
during their hospital stay cannot take oral medications. For
these individuals, an alternative method of administration
is also necessary.
Studies have demonstrated that certain tablets can be
administered through naso-gastric (NG) and gastrostomy
tubes using a syringe [14]. In fact, one study demonstrated
that crushed tablets of clopidogrel can be mixed with water
and flushed down an NG feeding tube [14]. Despite the
potential effects on the pharmacokinetics of the drug, it has
been suggested that this route of delivery will be unlikely
to cause any adverse events and may therefore provide a
viable alternative to oral tablets for patients with swal-
lowing difficulties [14].
The present ex vivo study was designed to investigate
the potential use of ticagrelor as a crushed dose and pre-
pared to emulate administration orally or via an NG tube.
2 Materials and Methods
Standard 90-mg ticagrelor tablets were prepared by similar
methods to emulate oral and NG tube administration; two
doses (90 and 180 mg [two 90-mg tablets]) of ticagrelor
were examined. For each method, one or two tablets were
placed into a heavy glass mortar and crushed for 60 s with
a glass pestle to form a powder. Purified water was used to
disperse the crushed tablets.
2.1 Oral Dose Administration
A schematic diagram of oral dose administration is shown
in Fig. 1. A ticagrelor tablet was placed in a mortar and
crushed for 60 s using a pestle. The crushed tablet was
transferred to a dosing cup, ensuring that all powder was
transferred and none remained on the mortar and pestle.
100 mL of purified water was added to the mortar and
stirred for 60 s using the pestle. The total contents of the
mortar were transferred to the dosing cup and stirred for an
additional 60 s using the pestle to ensure that all powder
was dispersed. The mortar was flushed with another
100 mL of purified water and stirred for 30 s using the
pestle. The total contents were transferred to another dos-
ing cup and stirred for another 30 s to ensure that all
remaining tablet particles were dispersed. Each of the
suspensions, which would normally be administered to a
patient from the dosing cup, was collected for high per-
formance liquid chromatography (HPLC) analysis of drug
recoverability.
2.2 NG Dose Administration
A schematic diagram of NG dose administration is shown in
Fig. 2. Three types of NG tube were used in the study:
polyvinylchloride (PVC), polyurethane (PUR), and silicone.
PUR and PVC tubes were 110 cm in length, silicone tubes
were 85 cm in length and all tubes were size CH10. Each NG
tube was flushed with 25 mL of purified water using a 50-mL
PVC oral enteral syringe. Ticagrelor tablets (90 or 180 mg
[two 90-mg tablets]) were placed in a mortar and crushed for
60 s using a pestle. 50 mL of purified water (for both the 90-
and 180-mg doses) was added to the mortar and stirred for
60 s using the pestle. The suspension was taken from the
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mortar using a 50-mL PVC oral enteral syringe, which was
then connected to the NG tube at the Luer-lock connection,
and the contents, which would normally be administered to a
patient at this stage, were passed through the NG tube and
collected for HPLC analysis of drug recoverability. Another
50 mL of purified water was added to the mortar and the
contents were stirred with the pestle for 60 s. The suspension
was removed from the mortar using the same 50-mL oral
enteral syringe, which was again connected to the NG tube at
the Luer-lock connection, and the contents were passed
through the NG tube and collected for HPLC analysis.
Another 50 mL of purified water was added to the mortar and
stirred with the pestle for 60 s. The suspension was again
removed from the mortar using the same 50-mL oral enteral
syringe, which was connected to the NG tube at the Luer-
lock connection, and the contents were passed through the
NG tube and collected for HPLC analysis. Finally, using the
same 50-mL PVC oral enteral syringe, 25 mL of purified
water was flushed through the NG tube. Each of the collected
flushes was analyzed separately by HPLC.
2.3 Sample Analysis
In order to determine the recoverability of ticagrelor, the
flushes for each method were prepared for HPLC analysis
and collected in volumetric flasks. The collected oral doses
and flushes were each diluted up to 200 mL with 70/30
(volume/volume [v/v]) acetonitrile/water; the collected NG
tube doses and flushes were each diluted up to 100 mL
with 70/30 (v/v) acetonitrile/water. A 10-mL aliquot of the
180-mg samples was diluted up to 20 mL with 35/65 (v/v)
acetonitrile/water. The concentration of ticagrelor was
Fig. 1 Schematic diagram of
oral administration. HPLC high
performance liquid
chromatography
Fig. 2 Schematic diagram of NG tube administration. NG naso-gastric, HPLC high performance liquid chromatography, PVC polyvinylchloride
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determined by comparing the values from HPLC analysis
of the ticagrelor sample with values from a ticagrelor ref-
erence standard solution prepared at a similar nominal
concentration and analyzed in the same way. The ticagrelor
sample and reference standard solutions were analyzed by
isocratic reversed phase HPLC and ultraviolet detection
using appropriate column and chromatographic conditions.
The amount of drug recovered was expressed as a per-
centage of the total intact ticagrelor dose (either 90 or
180 mg [label claim]). Experiments for each method were
repeated three times. The results were expressed as the
mean percentage of recovery of the intact dose. Release
testing, including measurement of ticagrelor tablet content
uniformity, was performed using standardized methods.
The in-use stability of the aqueous suspensions of
ticagrelor tablets (90- and 180-mg doses) held within the
50-mL PVC oral enteral syringe for up to 2 h (i.e., 0, 1, and
2 h) was examined. HPLC analysis measured the degra-
dation products.
3 Study Endpoints
The primary endpoint of the study was the mean percent-
age of ticagrelor recovered from the samples compared
with the intact tablet dose for each method of administra-
tion, for both the 90- and 180-mg ticagrelor doses.
Recovery was considered acceptable if the average recov-
ery exceeded 95 %.
The in-use stability of aqueous suspensions of ticagrelor
tablets, in terms of the observed level of degradation, was
also quantified.
4 Results
Data for the mean percentage recovery of ticagrelor are
shown in Table 1.
An acceptable level of recovery was reported for the 90-
and 180-mg doses for both routes of administration. For the
90-mg dose, silicone NG tubes provided a mean recovery
of 101 % (mean range 97–115 %), whereas PUR NG tubes
provided a mean recovery of 100 % (mean range
95–104 %) and PVC NG tubes provided a mean recovery
of 99 % (mean range 98–101 %). The results for the
180-mg dose for all three types of NG tube were similar
(mean range 97–98 %) as were results for the 90- and
180-mg crushed oral doses (mean range 98–100 %).
Recovery across administration methods was higher for the
90-mg doses of ticagrelor, compared with the 180-mg
doses.
There were no signs of degradation (i.e., any individual
degradation product\0.2 % weight/weight [w/w] and total
degradation products \0.5 % w/w) in the 90- and 180-mg
suspensions of ticagrelor when retained in a syringe for up
to 2 h.
5 Discussion
The recommended treatment for ACS is dual antiplatelet
therapy, and while it is effective [9, 15–17], it is often
challenging to administer the indicated dose to patients
who have difficulty swallowing. An alternative method of
oral administration, which circumvents the need to swallow
whole tablets, would provide an alternative option for these
patients.
Results from the current study demonstrated that cru-
shed tablets prepared to emulate oral or NG tube admin-
istration may provide patients with an acceptable method
of delivery of their ticagrelor dose. Results were uniform
for each route of delivery and for all three types of NG
tubes, and demonstrated greater than 97 % mean recover-
ability of the original dose. Release testing demonstrated
that the 90-mg ticagrelor tablets exhibited acceptable
content uniformity (acceptance value = 4.07, individual
tablet assay range 98.6–104.6 %). This variability in indi-
vidual tablet content uniformity may have contributed to
the relatively high individual dose recovery value reported
(114.47 %, Table 1).
The NG tubes investigated in this study were selected to
ensure compatibility with a range of tube materials used in
current clinical practice. Due to its small internal diameter
relative to other available tubes, the size of tube chosen for
this study (CH10) was considered to be worst-case with
respect to blockage or accumulation of material; therefore,
tubes of equivalent or greater size can potentially be used
for this method of administration.
Suspensions of ticagrelor held for up to 2 h in the syr-
inge did not show signs of degradation in this study. This
may be an important factor in clinical practice, as the









Crushed oral dose 99.47 [98.43–100.08] 99.20 [98.19–100.05]
NG tube
PVC 99.12 [97.86–100.68] 97.25 [96.45–97.98]
PUR 100.43 [95.28–103.89] 97.92 [97.26–98.97]
Silicone 101.37b [96.92–114.47] 97.29 [97.06–97.42]
NG naso-gastric, PUR polyurethane, PVC polyvinylchloride
a Average of three experiments
b Average of five experiments
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amount of time required to prepare and administer a cru-
shed dose of ticagrelor to a patient should fall well within
this timespan.
6 Conclusion
Although the routes of administration reported in this study
are not approved for ticagrelor, the results suggest that
ticagrelor tablets can be crushed and prepared for oral and
NG tube administration. Furthermore, previous studies
conducted in healthy volunteers and using electronic sen-
sory testing equipment have failed to indicate that ticagr-
elor has any adverse or unpalatable taste [18, 19]. Future
studies are required to test the effect of crushed dosing on
pharmacokinetic and pharmacodynamic parameters.
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